Predicting therapy-related myeloid neoplasms - and preventing them?
Menées respectivement à partir de données sur 14 patients atteints d'un lymphome et sur 54 témoins, et à partir de données portant sur 13 patients âgés de plus de 70 ans et sur 56 témoins, ces études rétrospectives analysent l'association entre une hématopoïèse clonale et le risque de développer des tumeurs malignes myéloïdes liées à la chimiothérapie
Therapy-related myeloid neoplasms are an iatrogenic tragedy. When a patient develops therapy-related myelodysplastic syndrome or acute myeloid leukaemia (ie, therapy-related myeloid neoplasms) several years after receiving curative treatment for another neoplasm, the unexpected and unwelcome return of frequent visits to a cancer centre and unearthing of old fears about mortality can be psychologically devastating. Alternatively, if a therapy-related myeloid neoplasm emerges while the patient is still receiving active therapy for a relapsed or refractory primary neoplasm, cytopenias associated with therapy-related myeloid neoplasms can make treatment of the other neoplasm with full therapeutic intensity impossible, and the presence of a therapy-related myeloid neoplasm usually excludes patients from innovative clinical trials for their other cancers.
The Lancet Oncology , commentaire, 2015